Patrick J. Grohar, MD, PhD
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)
Background
Patrick J. Grohar, MD, PhD is a pediatric oncologist and physician-scientist focused on the development of novel molecularly targeted therapies for pediatric solid tumors. After completing a B.S. in Chemistry at Villanova University, Dr. Grohar went on to complete both the MD and PhD degrees at Wayne State University. He completed pediatric training and a fellowship in hematology-oncology at Johns Hopkins University and the National Institutes of Health. He held faculty appointments at Vanderbilt University and the Van Andel Institute prior to his arrival at CHOP as an Associate Professor of Pediatrics and director of translational research within the Center for Childhood Cancer Research.
The Grohar Laboratory employs a bench to bedside and back again approach to develop targeted therapies for pediatric solid tumors. The laboratory has focused primarily on the therapeutic targeting of the EWS-FLI1 transcription factor for Ewing sarcoma. EWS-FLI1 is the clear oncogenic driver of Ewing sarcoma but a challenging drug target. Our laboratory has employed a number of complementary approaches to directly target EWS-FLI1, develop targeted combination therapies and identify novel drug targets. We have a number of studies in various stages of clinical translation. More recently, we have employed similar approaches to develop targeted therapies focused on other pediatric solid tumors that are dependent on similar drug targets and are characterized by few other somatic mutations.
Dr. Grohar is recognized for his work in Ewing sarcoma. He holds leadership positions within the Center for Childhood Cancer Research at CHOP and nationally within the Children’s Oncology Group. He is the Vice-Chair for Biology of the Bone Tumor Committee, Co-Chair of Combined Sarcoma Biology Committee and Chair of the Ewing Sarcoma Biology Committee. He is a Principal Investigator with the Sarcoma Alliance for Research through Collaboration. He serves as an ad hoc journal for multiple journals, the National Institutes of Health and for the Cancer Prevention Research Institute of Texas (CPRIT).
Education and Training
Medical School
MD - Wayne State University, Detroit, MI
Residency
Pediatrics, Research Track - Johns Hopkins University, Baltimore, MD
Fellowship
Hematology/Oncology - Johns Hopkins University, Baltimore, MD / National Institutes of Health, Bethesda, MD (Chief Fellow)
Board Certification
Pediatric Hematology-Oncology – American Board of PediatricsPediatrics – American Board of Pediatrics
Graduate Degree
PhD in Chemistry and Biochemistry - Wayne State University, Detroit, MI
Titles and Academic Titles
Attending Physician
Senior Research Scientist
Director, Translational Research, Center of Childhood Cancer Research
Kelly and Chad Punchard Endowed Chair in Translational Sarcoma Research
Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Conditions Treated
Departments and Services
Research Topics
Publications
Papers
2021
Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021;68(9):e29188. Epub 2021/06/18. doi: 10.1002/pbc.29188. PubMed PMID: 34137164; PMCID: PMC8316376.
2020
Chasse MH, Johnson BK, Boguslawski EA, Sorensen KM, Rosien JE, Kang MH, Reynolds CP, Heo L, Madaj ZB, Beddows I, Foxa GE, Kitchen-Goosen SM, Williams BO, Triche TJ, Jr., Grohar PJ. Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Mol Med. 2021;13(2):e12640. Epub 2020/12/18. doi: 10.15252/emmm.202012640. PubMed PMID: 33332735; PMCID: PMC7863405.
Kinnaman MD, Zhu C, Weiser DA, Mohiuddin S, Hingorani P, Roth M, Gill J, Janeway KA, Gorlick R, Lessnick SL, Grohar PJ. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma. 2020;2020:3498549. Epub 2021/01/26. doi: 10.1155/2020/3498549. PubMed PMID: 33488267; PMCID: PMC7787769 advisor for Salarius Pharmaceuticals and has patents related to NKX2.2 and GSTM4 in Ewing sarcoma.
Gedminas JM, Chasse MH, McBrairty M, Beddows I, Kitchen-Goosen SM, Grohar PJ. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis. 2020;9(4):41. Epub 2020/04/30. doi: 10.1038/s41389-020-0224-1. PubMed PMID: 32345977; PMCID: PMC7188842.
Flores G, Everett JH, Boguslawski EA, Oswald BM, Madaj ZB, Beddows I, Dikalov S, Adams M, Klumpp-Thomas CA, Kitchen-Goosen SM, Martin SE, Caplen NJ, Helman LJ, Grohar PJ. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. Mol Cancer Ther. 2020;19(5):1183-96. Epub 2020/03/05. doi: 10.1158/1535-7163.Mct-19-0775. PubMed PMID: 32127464.
2019
Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, Widemann BC, Heller T, Schrump DS, Figg WD. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. Mol Pharmacol. 2019;96(2):158-67. Epub 2019/06/09. doi: 10.1124/mol.118.114827. PubMed PMID: 31175181; PMCID: PMC6608607.
Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019;8. Epub 2019/04/30. doi: 10.12688/f1000research.18139.1. PubMed PMID: 31031965; PMCID: PMC6468706.
Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Clin Cancer Res. 2019;25(11):3417-29. Epub 2019/02/07. doi: 10.1158/1078-0432.Ccr-18-3511. PubMed PMID: 30723142; PMCID: PMC6594545.
2017
Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80(3):645-52. Epub 2017/07/25. doi: 10.1007/s00280-017-3382-x. PubMed PMID: 28735378; PMCID: PMC6413860.
Pridgeon MG, Grohar PJ, Steensma MR, Williams BO. Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. Curr Osteoporos Rep. 2017;15(4):239-46. Epub 2017/06/26. doi: 10.1007/s11914-017-0377-9. PubMed PMID: 28647886.
Grohar PJ, Janeway KA, Mase LD, Schiffman JD. Advances in the Treatment of Pediatric Bone Sarcomas. Am Soc Clin Oncol Educ Book. 2017;37:725-35. Epub 2017/06/01. doi: 10.1200/edbk_175378. PubMed PMID: 28561686; PMCID: PMC6066791.
2016
Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ, Berdel WE, Burdach S. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Sarcoma. 2016;2016:7461783. Epub 2016/11/16. doi: 10.1155/2016/7461783. PubMed PMID: 27843394; PMCID: PMC5098094.
Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Res. 2016;76(22):6657-68. Epub 2016/11/05. doi: 10.1158/0008-5472.Can-16-0568. PubMed PMID: 27697767; PMCID: PMC5567825.
Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. (18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep. 2016;6:33926. Epub 2016/09/28. doi: 10.1038/srep33926. PubMed PMID: 27671553; PMCID: PMC5037393.
Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clin Cancer Res. 2016;22(16):4105-18. Epub 2016/03/17. doi: 10.1158/1078-0432.Ccr-15-2624. PubMed PMID: 26979396; PMCID: PMC4987166.
Caropreso V, Darvishi E, Turbyville TJ, Ratnayake R, Grohar PJ, McMahon JB, Woldemichael GM. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells. J Biol Chem. 2016;291(19):10058-66. Epub 2016/03/11. doi: 10.1074/jbc.M115.701375. PubMed PMID: 26961871; PMCID: PMC4858959.
Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016;7(8):8613-24. Epub 2016/01/24. doi: 10.18632/oncotarget.6937. PubMed PMID: 26802024; PMCID: PMC4890991.
Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Rep. 2016;14(3):598-610. Epub 2016/01/19. doi: 10.1016/j.celrep.2015.12.063. PubMed PMID: 26776507; PMCID: PMC4755295.
Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ, D'Incalci M. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemother Pharmacol. 2015;75(6):1317-20. Epub 2015/03/27. doi: 10.1007/s00280-015-2726-7. PubMed PMID: 25809543.
Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014;20(5):1190-203. Epub 2013/11/28. doi: 10.1158/1078-0432.Ccr-13-0901. PubMed PMID: 24277455; PMCID: PMC5510643.
Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL. A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Front Oncol. 2013;3:57. Epub 2013/03/23. doi: 10.3389/fonc.2013.00057. PubMed PMID: 23519678; PMCID: PMC3602933.
Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013;32(47):5429-38. Epub 2013/01/16. doi: 10.1038/onc.2012.590. PubMed PMID: 23318429; PMCID: PMC3898328.
Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther. 2013;137(2):216-24. Epub 2012/10/23. doi: 10.1016/j.pharmthera.2012.10.004. PubMed PMID: 23085431; PMCID: PMC7243921.
Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011;103(12):962-78. Epub 2011/06/10. doi: 10.1093/jnci/djr156. PubMed PMID: 21653923; PMCID: PMC3119649.
Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13(2):145-53. Epub 2011/03/16. doi: 10.1593/neo.101202. PubMed PMID: 21403840; PMCID: PMC3033593.
Flores G, Everett JH, Boguslawski EA, Oswald BM, Madaj ZB, Beddows I, Dikalov S, Adams M, Klumpp-Thomas CA, Kitchen-Goosen SM, Martin SE, Caplen NJ, Helman LJ, Grohar PJ. CDK9 Blockade Exploits Context-Dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. Mol Cancer Ther. 2020 Mar 3. pii: molcanther.0775.2019. doi: 10.1158/1535-7163.MCT-19-0775. [Epub ahead of print]
2019
Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, Widemann BC, Heller T, Schrump DS, Figg WD. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7. PMID: 31175181
Bailey, K. M., Cost, C. R., Davis, I. J., Glade-Bender, J., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E., Laack, N., Yustein, J. T., Reed, D. R., Janeway, K. A., Gorlick, R., Lessnick, S. L., DuBois, S. G., Hingorani, P.: Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) new agents for Ewing sarcoma task force. F1000Res. 2019 Apr 15;8. pii: F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1. eCollection 2019.
Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB5, Taslim C6, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ: Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule Dependent Manner. Clin Cancer Res. 2019 Feb 5. doi: 10.1158/1078-0432.CCR-18-3511. [Epub ahead of print]
2017
Grohar PJ, Janeway KA, Mase LD, Schiffman JD. 2017. Advances in treatment of pediatric sarcomas. Am Soc Clin Oncol Educ Book 37:725–735.
Grohar Patrick J, Glod John, Peer Cody J, Sissung Tristan M, Arnaldez Fernanda I, Long Lauren, Figg William D, Whitcomb Patricia, Helman Lee J, Widemann Brigitte C: A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer chemotherapy and pharmacology 80(3): 645-652, Sep 2017.
Pridgeon Matthew G, Grohar Patrick J, Steensma Matthew R, Williams Bart O: Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. Current osteoporosis reports 15(4): 239-246, Aug 2017.
2016
Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D’Incalci M, von Leuttichau I, Grohar PJ, Berdel WE, Burdach S. 2016. Trabectedin followed by irinotecan can stabilize disease in advanced translocation-positive sarcomas. Sarcoma.
Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar PJ, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. 2016. The second European interdisciplinary Ewing sarcoma research summit—A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget 7:8613–8624.
Harlow Matt L, Maloney Nichole, Roland Joseph, Guillen Navarro Maria Jose, Easton Matthew K, Kitchen-Goosen Susan M, Boguslawski Elissa A, Madaj Zachary B, Johnson Ben K, Bowman Megan J, D'Incalci Maurizio, Winn Mary E, Turner Lisa, Hostetter Galen, Galmarini Carlos María, Aviles Pablo M, Grohar Patrick J: Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer research 76(22): 6657-6668, Nov 2016.
Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar P J, Berdel W E, Burdach St: Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Sarcoma Page: 7461783, Oct 24 2016 Notes: Epub only.
Osgood Christy L, Tantawy Mohammed N, Maloney Nichole, Madaj Zachary B, Peck Anderson, Boguslawski Elissa, Jess Jennifer, Buck Jason, Winn Mary E, Manning H Charles, Grohar Patrick J: F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Scientific reports 6(1): 33926, Sep 2016.
Osgood Christy L, Maloney Nichole, Kidd Christopher G, Kitchen-Goosen Susan, Segars Laura, Gebregiorgis Meti, Woldemichael Girma M, He Min, Sankar Savita, Lessnick Stephen L, Kang Min, Smith Malcolm, Turner Lisa, Madaj Zachary B, Winn Mary E, Núñez Luz-Elena, González-Sabín Javier, Helman Lee J, Morís Francisco, Grohar Patrick J: Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical cancer research : an official journal of the American Association for Cancer Research 22(16): 4105-18, Aug 2016.
Caropreso Vittorio, Darvishi Emad, Turbyville Thomas J, Ratnayake Ranjala, Grohar Patrick J, McMahon James B, Woldemichael Girma M: Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells. The Journal of biological chemistry 291(19): 10058-66, May 2016.
Grohar Patrick J, Kim Suntae, Rangel Rivera Guillermo O, Sen Nirmalya, Haddock Sara, Harlow Matt L, Maloney Nichole K, Zhu Jack, O'Neill Maura, Jones Tamara L, Huppi Konrad, Grandin Magdalena, Gehlhaus Kristen, Klumpp-Thomas Carleen A, Buehler Eugen, Helman Lee J, Martin Scott E, Caplen Natasha J: Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell reports 14(3): 598-610, Jan 2016.
2015
Tancredi R, Zambelli A, DaPrada G A, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar P J, D'Incalci M: Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer chemotherapy and pharmacology 75(6): 1317-20, Jun 2015.
2014
Grohar Patrick J, Segars Laure E, Yeung Choh, Pommier Yves, D'Incalci Maurizio, Mendoza Arnulfo, Helman Lee J: Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clinical cancer research : an official journal of the American Association for Cancer Research 20(5): 1190-203, Mar 2014.
2013
Yeung C L, Ngo V N, Grohar P J, Arnaldez F I, Asante A, Wan X, Khan J, Hewitt S M, Khanna C, Staudt L M, Helman L J: Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene 32(47): 5429-38, Nov 2013.
Grohar Patrick J, Helman Lee J: Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacology & therapeutics 137(2): 216-24, Feb 2013.
2011
Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ. 2011. Ecteinascidin 743 (ET-743) interferes with the activity of EWS-FLI1 in Ewing’s sarcoma cells. Neoplasia 13(2):145–153.
Grohar Patrick J, Woldemichael Girma M, Griffin Laurie B, Mendoza Arnulfo, Chen Qing-Rong, Yeung Choh, Currier Duane G, Davis Sean, Khanna Chand, Khan Javed, McMahon James B, Helman Lee J: Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Journal of the National Cancer Institute 103(12): 962-78, Jun 2011.
Grohar Patrick J, Griffin Laurie B, Yeung Choh, Chen Qing-Rong, Pommier Yves, Khanna Chand, Khan Javed, Helman Lee J: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (New York, N.Y.) 13(2): 145-53, Feb 2011.
Awards and Honors
2018, Alex’s Lemonade Stand: Northwestern Mutual Innovative Grant Award
2017, St. Baldrick’s Scholar
2013-2015, Junior Faculty Development Program, Vanderbilt University School of Medicine
2011, Fellows Award for Research Excellence (FARE), National Institutes of Health
2010, Finalist, American Association for Cancer Research (AACR) Scholar in Training Award
2008-2010, Pediatric Oncology Branch Research Competition - 1st Place: Fellows Post Docs (Annually for three years), Johns Hopkins University/National Institutes of Health
2006-2011, Competitive National Institutes of Health Loan Repayment Program for General Research (5 renewals awarded)
Editorial and Academic Positions
Editorial Positions
Ad Hoc Reviewer
2019, Drug Discovery and Molecular Pharmacology (DMP)
2017-2018, National Institutes of Health, Cancer and Molecular Pathobiology (CAMP)
2017-present, Cancer Cell
2017-present, Science
2015-present, St. Baldrick’s Foundation
2011-present, PLOS one
2011-present, Frontiers in Medicine
2011-present, Oncotarget
2011-present, Cancer Research
2011-present, BMC Cancer
2011-present, Frontiers in Pediatrics
2011-present, Clinical Cancer Research
2011-present, International Journal of Nanomedicine
2011-present, Journal of Clinical Investigation
2011-present, Leukemia
2011-present, Genes and Cancer
2011-present, Sarcoma
2011-present, Molecular Cancer Research
Academic and Institutional Committees
2017-present, Cancer Prevention Research Institute of Texas (CPRIT), Cancer Biology Panel, standing member
2015-present, Alex’s Lemonade Stand, Scientific Review Board
Leadership and Memberships
Memberships in Professional Organizations
2017-present, Children’s Oncology Group Therapeutic Task Force
- 2019-present, Osteosarcoma
- 2017-present, Ewing Sarcoma
2016-present, QuadW-Biospecimen Committee
2011-present, Connective Tissue Oncology Society
2011-present, Children’s Oncology Group
2009-present, American Association for Cancer Research
Leadership
2019-present, Vice-Chair for Biology, Bone Tumor Committee
2019-present, Chair, Ewing Sarcoma Biology Committee
2015-present, Children’s Oncology Group, Bone Tumor Steering Committee
2015-2019, Vice-Chair, Ewing Sarcoma Biology Committee
2018-present, Co-Chair, Combined Sarcoma Biology Committee